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The aim of this study was to design a compound transdermal patch containing diclofenac
(DA) and teriflunomide (TEF) for the treatment of rheumatoid arthritis (RA). The various
organic amines salts of DA were prepared and their forming was confirmed using DSC and
FTIR. The percutaneous permeation of organic amines salt of DA was investigated in vitro
using a two-chamber diffusion cell with excised rabbit skin as transdermal barrier. The
formulation of the patch was optimized in terms of the concentration of percutaneous
permeation enhancer and the loading dose of drugs. The pharmacokinetic behavior of the
optimal formulation was studies in rabbits and the anti-inflammatory and analgesic effects
of the optimal patch were evaluated with the adjuvant arthritis model in rats and the pain
model in mice, respectively. The result showed that skin penetration of diclofenac-
triethylamine (DA-TEtA) salt was better than other organic amine salts. Based on previ-
ous study of our laboratory, teriflunomide-triethylamine (TEF-TEtA) significantly enhanced
the skin permeation of TEF. 10% of azone (AZ) was the best enhancer for the two drugs. The
optimal patch formulation was composed of 2% of TEF-TEtA, 6% of DA-TEtA and 10% of AZ.
The cumulative permeated amount of DA-TEtA in vitro was comparable with that of the
commercial diclofenac-diethylamine (DA-DEtA) patch. The absolute bioavailability of TEF-
TEtA was 42%, which could achieve the therapeutic drug levels. In animal study, the
optimized compound patch containing DA-TEtA and TEF-TEtA displayed significant anti-
inflammatory and analgesic effect, which indicated the potential of the compound patch.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.aceutical Science, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua
6 24 23986330.
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Rheumatoid arthritis (RA) is a long-term and chronic inflam-
matory disease caused by the immune system attacking
joints, which is characterized by symmetrical distribution [1].
Chronic synovitis attacks cartilage articularis, ligament and
muscle tendon, leading to joint deformity and functional
disorder. Nonsteroidal anti-inflammatory drugs (NSAIDs) are
widely used for the treatment of musculoskeletal disorders
such as osteoarthritis and rheumatoid arthritis [2]. However,
there is no evidence to show that NSAIDs can delay the pro-
gression of RA [3]. On the other hand, disease-modifying anti-
rheumatic drugs (DMARDs) could prevent the pathological
process of RA and avoid the joint damage but could not relieve
the pain immediately [4]. Considering thatmonotherapies and
fixed-dose can not meet the needs of different patients,
NSAIDs and DMARDs are always used in combination for RA
treatment clinically since 1950s [5].
Diclofenac(2-[2-(2,6 dichlorophenyl amino) phenyl]acetic
acid) is one of the most prospective and commercially suc-
cessful drug in the family of NSAIDs [6,7] and has an annual
turnover over 1 billion US dollars [8]. It is used for the treat-
ment of rheumatoid arthritis, osteoarthritis and relief the pain
of varying origin treatment [9]. Themainmechanism of action
is to inhibit the activity of cyclooxygenase (COX) by inter-
dicting the prostaglandin (PG) synthesis [10]. However the
main disadvantage of oral administrated diclofenac dosage
form is the serious adverse effects such as gastrointestinal
disturbances, nausea, vomiting and stomach pain, etc [11].
Leflunomide (LEF) is one of DMARDs, which has been rec-
ommended for RA therapy by the American College of Rheu-
matology [12]. The LEF is transferred into its active metabolite
teriflunomide (TEF) and TEF plays the major role for therapy
[13,14]. It was shown TEF could inhibit the production of PGE2
and the activity of cyclooxygenase-2 (COX-2) [15]. However, up
to 50% of patients showed intolerability to this drug after oral
administration, especially suffering from some gastrointes-
tinal adverse effects [16]. With regarding to this, another
administrating route avoiding the severe adverse effects is
desired for delivering of the combination of DA and TEF into
the body.
Transdermal drug delivery system (TDDS) is a promising
alternative way of drug delivery which can maintain a uni-
form plasma concentration, reduce dosing frequency associ-
ated with improved the patient compliance, and avoid the
gastrointestinal action. The compound transdermal patch
containing DA and TEF will not only avoid the gastrointestinal
irritation, but also provide double response of controlling RA
activity. It has been reported that the skin permeation of weak
acidic DA and TEF (Table 1) is unsatisfactory, but the addition
of organic amines can significantly increase the percutaneous
permeability of TEF [12] and DA [17,18]. Therefore, the exper-
iment firstly prepared the different origin amine salts of DA
and screened the salt with the optimal permeation. Based on
previous study of our laboratory [12], TEF-TEtA significantly
enhanced the skin permeation of TEF and the effect of
different chemical enhancers had been investigated. The best
concentration of enhancer for two drugs and the loading dose
of drugs were chosen. There is no commercial transdermalproduct of TEF, so the pharmacokinetics study of TEF is used
to confirmwhether the loading dose of TEF-TEtA is reasonable
or not. To investigate the anti-inflammatory and analgesic
effects of the compound patch, the pharmacodynamic study
was carried out finally.2. Materials and methods
2.1. Chemisty and materials
DA, diclofenac-sodium (DA-Na), diclofenac-potassium (DA-K),
and diclofenac-diethylamine (DA-DEtA) were purchased from
Tiande Pharmaceutical Co. Ltd (Tieling, China). TEF and TEF-
TEtA were synthesized in our laboratory [12]. Pressure sensi-
tive adhesive (PSA) was supplied by Henkel Corp., (New Jersey,
USA). Korean commercial DA-DEtA patch was obtained from
Samyang. Corp., (Korea). Complete Freund's adjuvant (CFA)
was purchased from SigmaeAldrich Co. LLC., (Missouri, USA).
Propylparaben was obtained from Bodi Chemical Holding Co.
Ltd., (Tianjin, China). Diethanolamine (DEA), triethanolamine
(TEA), triethylamine (TEtA), propylparaben were all obtained
from Bodi Chemical Holding Co. Ltd., (Tianjin, China). 1-(2-
Hydroxyethyl) pyrrolidine (NL) was purchased from Tianjin
Heowns Biochem LLC, N-(2-Hydroxyethyl) piperidine (NP) was
supplied by Alfa Aesar (Massachusetts, USA). N-methyl pyr-
rolidone (NMP), azone (AZ), isopropyl myristate (IPM), Trans-
cutol® P (TP), oleic acid (OA), Span 80, propylene glycol (PG)
and L-menthol (MT) were obtained from International Spe-
cialty Products Inc., (New Jersey, USA), Tianmen Kejie Phar-
macy Co. Ltd., (Hubei China), China National Medicines Co.
Ltd., (Shanghai, China), Beijing Chemical Co. Ltd., (Beijing,
China), Tianjin Bio Chemical Co. Ltd., (Tianjin, China), Tianjin
Bio Chemical Co. Ltd., (Tianjin, China), Nanjing chemical re-
agent Co. Ltd., (Nanjing, China) and Suzhou Healthytech Bio-
Pharmaceutical Co. Ltd., (Jiangsu, China), respectively. All
other chemicals and solvents were analytical reagent grade.
2.2. Animals
Rabbits (male, 1.8e2.2 kg), Wistar rats (male, 180e220 g) and
KM mice (male, 18e22 g) used all in the experiments were
purchased from the Experimental Animal Center of Shenyang
Pharmaceutical University (Shenyang, China). The experi-
ments were performed in accordance with the guidelines for
animal use published by the Life Science Research Center of
Shenyang Pharmaceutical University.
2.3. Synthesis of organic amine salts of DA
DA was completely dissolved in acetone and then equimolar
of organic amines was added. After the mixture of DA and
organic amine was subjected to ultrasound for 1 h at room
temperature, the solvents were removed by using rotary
evaporator. The obtained solid product was further dried in a
vacuum oven for 24 h at room temperature. The synthesis of
organic amine salt was confirmed by DSC (DSC1 STARe Sys-
tem, Mettler-Toledo International Inc., Schwerzenbach,
Switzerland) and FTIR (Spectrum 100, PerkinElmer Inc., Mas-
sachusetts, USA) respectively.
Table 1 e Physicochemical properties of DA and TEF.
Chemical structure M.W. log P pKa t1/2
Diclofenac (DA) 296.15 4.75 3.6 1.1e1.8 h
Teriflunomide (TEF) 270.21 2.51 5.2 14 day
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Transdermal patches were prepared by the solvent evapora-
tion technique. In brief, specific amount of drug, PSA and
enhancer were dissolved in ethanol by mechanically stirred
for 1 h. The obtained homogeneous solutionwas spread onto a
silicone-coated release liner (Shanghai Fupeng Adhesive
Products Co. Ltd, China) with a thickness of 80 mm. After it was
settled at the room temperature for 10 min, the samples were
heated in an oven at 50 C for 10min to completely remove the
solvent. Finally, the samples were covered with a fabric
backing film (Hangzhou Xiaoshan Johnson Cloth Factory,
Zhejiang, China).2.5. In vitro permeation experiments
2.5.1. Preparation of excised rabbit skin
After rabbits were anesthetized with urethane (20%, w/v, i.v.),
hair on abdominal skin was removed by electric clipper and
followed shaved carefully using a razor. Full thickness skin
including epidermis with SC and dermis was excised, and the
subcutaneous fat was carefully removed using the surgical
scissor and scalpel. The excised skinwaswashed immediately
with phosphate-buffered saline and ready for use. If neces-
sary, the skin samples can be frozen at 70 C for storage for
maximum 1 month.
2.5.2. The skin permeation experiments
The rate of DA or its organic amine salts penetrating through
the excised rabbit abdominal skin was evaluated by using a
two-chamber glass diffusion cell with the effective diffusion
area of 0.95 cm2. After the device was assembled, the patch
was applied on the stratum corneum side of skin that was
clamped between the two chambers. The receiver cell was
filled with 3 ml of phosphate-buffered saline (PBS, pH 7.4) as
receive medium and the media was stirred at the rate of
600 rpm to ensure the uniformity with a magnetic bead. The
temperature of the medium was maintained at 32 C by a
circulating-water jacket during thewhole experiment. At each
predetermined time point, 2.0 ml of received medium was
withdrawn from the receptor and an equal volume of fresh
PBS buffer was added to keep a constant volume. 200 ml of the
withdrawn sample wasmixed with 200 ml of internal standard
solution (propylparaben, 25 mg/ml) for High Performance
Liquid Chromatograph (HPLC) analysis.2.6. Pharmacokinetic study
2.6.1. The preparation of injection TEF
Weight 10 mg TEF to a 10 ml volumetric flask, dissolve in 3 ml
ethanol, dilute with physiologic saline to volume, and mix.
2.6.2. Dosage regimen design
A total of 9 male rabbits (1.8e2.2 kg) were randomly divided
into 3 groups for pharmacokinetics study of TEF via i.v. in-
jection, transdermal compound patch and Korean commer-
cial DA-DEtA patch, respectively. Rabbits in group A were i.v.
injection 4 mg TEF separately and for group B and C self-
prepared and commercial patch with the same area of
20 cm2 was administrated respectively. Prior to the applica-
tion of patch the hair on abdominal skin was removed and the
skin cleaned. Blank blood samples were withdrawn right
before administration and at 5, 10, 15, 30, 45min, 1, 1.25, 1.5, 2,
3, 4, 5, 6, 7, 8, 10, 12, 24, 26, 32, 48, 60, 72 h after the adminis-
tration of patch blood samples were continuously withdrawn.
For group A, the blood samples were withdrawn at 0, 5, 15,
30min, 1, 2, 3, 4, 6, 8, 10, 12, 14, 24 h. Subsequently, the plasma
samples were separated by centrifugation and frozen
at 70 C until analysis.
2.6.3. Plasma sample extraction process
The plasma sample (100 ml) and internal standard (60 mg/ml,
10 ml) were mixed in a 1.5 ml Eppendorf tube by vortex-mixing
for 1 min. Protein in the plasma samples was precipitated by
the addition of 1 ml acetonitrile [19] followed by extra vortex
for 3 min, and centrifugation at 16,000 rpm for 5 min. The
supernatant was transferred to another new tube and evap-
orated to dryness under nitrogen at 40 C. 100 ml mobile phase
was added into the residue for reconstitution and the mixture
was vortex-mixed for 3 min and centrifuged at 16,000 rpm for
5 min. Finally, the supernatant was injected into HPLC system
for analysis.2.7. HPLC analysis
The concentration of DA and TEF in the receptor medium and
plasma was quantitatively determined by HPLC method. The
HPLC system contained a pump L-2130, an ultraviolet detector
L-2420, an automatic injector L-2200 and a T2000L worksta-
tion. C18 column (200 mm  4.6 mm, 5 mm) was used for the
separation of samples. Mobile phase was a mixture of
Fig. 1 e FTIR spectra for DA and its organic amine salts.
Fig. 3 e The penetration profiles of transdermal patches
containing DA or its salts (n¼3).
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adjusted to pH6.8 with TEtA. The flow-rate of mobile phase
was 1 ml/min and the analytes were monitored at 280 nm.2.8. Data analysis
The cumulative amount of drug penetrated per unit area
versus time (Q) was plotted. The slope of linear portion of the
plot was calculated as the flux (J, mg/cm2/h). Enhancement
ratio (ER) was the ratio of Q from the vehicle with amine
against that without amine or with enhancer against without
enhancer. Difference was checked with ANOVA considered to
be statistical significance at P < 0.05. Pharmacokinetic pa-
rameters were determined by non compartmental analysis
applying WinNonlin software, version 3.0.2.9. Pharmacodynamic study
2.9.1. Assessment of anti-inflammatory effect
The adjuvant arthritis model in rats was used to evaluate the
therapeutic effect of compound patch for RA [20]. 36 male ratsFig. 2 e DSC curves of the DA and its organic amine salts.weighting 180e220 g were randomly divided into 6 groups.
Specific details for each group were as follows:
 Control group: no administration
 Positive group: Korean commercial DA-DEtA patch (10 cm2,
DA 19.2 mg)
 Negative group: blank patch (10 cm2, without any drug)
 DA group: DA-TEtA patch (10 cm2, DA 10 mg)
 TEF group: TEF-TEtA patch (10 cm2, TEF 3 mg)
 DA/TEF group: the compound patch (10 cm2, DA 10mg, TEF
3 mg)
0.1 ml of the Complete Freund's Adjuvant (CFA) or physi-
ological saline (for the control group) was injected into both
side of the hind paw of rats. A water plethysmometer
(YLSe7B, Jinan Yiyan Technology Co. Ltd., Shangdong, China)
was used tomeasure the volume of bilateral hind paw at 0, 0.5,
3, 5, 7, 9, 11 days after injection of CFA. The keen-joint
was supplied the transdermal patch at the swelling peakFig. 4 e The penetration profiles of DA-TEtA transdermal
patches containing 10% various chemical enhancers (n¼3).
Fig. 5 e (a) The penetration profiles of adding different
concentrations of AZ on percutaneous absorption of DA-
TEtA. (b) The penetration profiles of adding different
concentrations of AZ on percutaneous absorption of
TEF-TEtA (n¼3).
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Swelling Degree (S). The Swelling Degree (S) was calculated
from the following formula:
S

%
 ¼ Vt  Vn
Vn
 100
Where Vn was the paw volume before the injection of CFA or
physiological saline; Vt was the paw volume at the t day.Table 2 e The penetration parameters of Korean commercial p
Permeants DA-TEtA
Q24h (mg/cm
2) J (mg/c
F-1 370.96 ± 36.95 8.54
F-2 593.56 ± 40.82 24.36
F-3 1007.11 ± 99.96 36.6
Commercial patch 1034 ± 46.92 46.252.9.2. Assessment of analgesic effect
Writhing induced by acetic acid was used to assess the anal-
gesia effect of compound patch for RA. Male mice (18e22 g)
were randomly divided into 6 groups and each group was
consisted of 10 animals. The grouping scheme was the same
as the section 2.9.1 except the area of transdermal patch
administrated was 5 cm2 instead of 10 cm2. The hair on the
abdominal skin of the mice was removed 12 h prior to the
application of patch. After 2 h's application, the patches were
removed and then 0.1 ml/10 g weight of 0.6% (v/v) acetic acid-
saline was injected intraperitoneally. Five minutes later, the
number of writhing (W) within 20 min was recorded. The pain
inhibition ratio (PIR) was calculated according to the following
formula:
PIR ¼Wblank Wadministration
Wblank
 100%
W was the writhing numbers.3. Results and discussion
3.1. Confirming the formation of organic amine salts of
DA
3.1.1. FTIR spectroscopy
The FTIR spectroscopy measurement was carried out to
confirm the salts formation between DA and organic amines.
The FTIR spectra for DA and its salts were shown in Fig. 1. It
was observed that DA showed a strong absorption at
1694 cm1, which was assigned to stretching vibration of C]O
of COOH group [21]. However, when the organic amines were
added, this absorption peak shifted to low wavenumber to
1639.4 cm1 for DA-DEA, 1604.2 cm1 for DA-TEA, 1674.3 cm1
for DA-TEtA, 1606.4 cm1 for DA-NL and 1605.0 cm1 for DA-
NP. It was suggested that addition of organic amines to DA
resulted in the change in the chemical shift of the carbonyl.
On the other hand, DA had a sharp signal peak at 3323.2 cm1
which was assigned to the OH stretching vibration. After the
addition of organic amines, the corresponding peak became
weaker and the peak position was shifted to different wave-
numbers. These results indicated that the formation of
hydrogen bond between the OH from the parent and the basic
N atom from organic amines resulted in the movement of OH
stretching vibration absorption peak.
3.1.2. DSC analysis
The DSC curves for DA and its salts were shown in Fig. 2. It
could be seen that DA presented a single sharp absorptionatch and different compound formulations (n ¼ 3).
TEF-TEtA
m2/h) Q24h (mg/cm
2) J (mg/cm2/h)
± 1.41 423.23 ± 42 18.84 ± 2.4
± 2.23 436.87 ± 22.45 20.2 ± 3.44
± 1.48 421.35 ± 21.21 13.35 ± 1.21
± 2.82 e e
Fig. 6 e Mean plasma concentration-time profiles of
different formulations. (a) i.v. TEF; (b) Korean commercial
patch; (c) DA/TEF compound patch.
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 5 1e2 5 9256peak at 178.95 Cwhich indicated that DA had a singlemelting
point. This result was consistent with the reported literature
[22]. However, the absorption peaks of DA-DEA, DA-TEA, DA-
TEtA, DA-NL, DA-NP appeared at 127.52 C, 136.67 C,
111.16 C, 105.22 C, 135.38 C, respectively. The melting point
of all organic amine salts was lower than DA.
The FTIR spectroscopy and DSC curves confirmed that the
organic amine salts of DA has been formed successfully.
3.2. Formulation optimization
Although most acrylic PSAs possessed the advantage of good
compatibility with a wide range of drugs, but some of them
were resistant to interaction with drugs because of the pres-
ence of some polar groups, which could cause the system
changed. In order to avoid the destruction, the type of PSA
without any polar group was selected as the adhesive matrix
in current study.
The cumulative permeation profiles of different salts of DA
were presented in Fig. 3. Even though the majority of salts of
DA included DA-NL, DA-NP, DA-DEtA did not show enhanced
cumulative permeation amount in 24 h (Q24) compared to DA,
significant increase of Q24 (ER ¼ 1.99) was achieved with DA-
TEtA. Therefore, DA-TEtA was used in following studies.
Although the permeation of DA has been significantly
enhanced by transforming DA into its salt DA-TEtA, the cu-
mulative permeation amount of DA-TEtA was not high
enough. Therefore, various chemical enhancers such as AZ,
OA, MT, IPM, TP, PG, NMP, Span 80 were employed. The effect
of enhancers in the vitro penetration of DA-TEtA was pre-
sented in Fig. 4. Apart from PG and NMP, all the enhancers
investigated could increase the penetration of DA-TEtA.
However, lipophilic enhancers such as AZ, OA, IPM had bet-
ter transdermal penetrate enhancing effect on DA-TEtA. It
was well known that the lipophilic stratum corneum was the
major barrier for TDDS [23]. While the addition of lipophilic
enhancersmight disrupt the order of lipid bilayers and change
the barrier function of stratum corneum to increase the allo-
cation of DA-TEtA to stratumcorneum [24]. On the other hand,
the enhancers consisting of OH groupsmoietymay disturb the
interaction of DA and organic amine. Considering the safety
and effectiveness of enhancer both to DA-TEtA and TEF-TEtA,
AZ was selected as the enhancer for the optimized formula-
tion. The effective of AZ on the permeation of TEF-TEtA has
been demonstrated previously [12].
Subsequently, we observed the maximum enhancing ef-
fect within 1%~15% concentration of range. As shown in Fig. 5,
the enhancement effect of AZ was concentration dependent
within the range of 1%~15% and there was no significant dif-
ference (P > 0.05) between 10% and 15% of AZ. Considering the
cost and appearance, 10% of AZwas chosen as the enhancer of
compound patch.
Since the formulation of the patch we designed to achieve
comparable Q24 of DA-TEtA with that of Korean commercial
DA-DEtA patch, the different loading drugs of DA-TEtA were
screened. Containing 4%, 5% and 6% of DA-DEtA was formu-
lation 1 (F-1), F-2 and F-3, respectively. The results were
showed in Table 2. The penetration parameter of F-3 was met
the requirement of experimental design. So the loading of DA-
TEtA was chosen as 6% of the weight of PSA.3.3. Pharmacokinetic study
Mean plasma concentration-time profiles obtained after
intravenous and transdermal patches administration were
presented in Fig. 6. The main pharmacokinetic parameters
were shown in Table 3.
Table 3 e The pharmacokinetic parameters of different formulations (n ¼ 3).
i.v. TEF Korean commercial patch DA/TEF patch
DA TEF
Dose (mg) 4 38.5 24 6
Tmax (h) e 2.5 ± 1.32 3.75 ± 2.4 5 ± 2.82
Cmax (mg/ml) 12.91 ± 1.71 1.91 ± 1.04 1.22 ± 0.34 1.90 ± 0.85
AUC (hmgml1) 39.36 ± 8.62 23.06 ± 8.33 18.1623 ± 2.38 26.14 ± 7.08
AUCM (hhmgml1) 132.42 ± 52 220.09 ± 18.22 199.11 ± 16.96 324.56 ± 28.88
MRT (h) 3.28 ± 0.57 10.15 ± 2.55 11.15 ± 1.84 12.73 ± 2.34
Fig. 7 e The profiles of swelling degree (%) of hind paw of
rats after CFA injection and transdermal patches applied
on left feet at 5 d: (a) left hind paw; (b) right hind paw
(n ¼ 6).
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 5 1e2 5 9 257There was no significant difference between the pharma-
cokinetic parameters of DA in Korean commercial patch and
the prepared DA/TEF patch with Tmax(time to peak) of
2.5 ± 1.32 h and 3.75 ± 2.4 h, Cmax of 1.91 ± 1.04 mg/ml
and 1.22 ± 0.34 mg/ml, AUC(area under the
concentration-time curve) of 23.06 ± 8.33 hmgml1
and 18.1623 ± 2.38 hmgml1, AUCM of
220.09± 18.22 hhmgml1 and 199.11± 16.96 hhmgml1
and MRT of 10.15 ± 2.55 h and 11.15 ± 1.84 h, respectively. It
suggested that the systemic concentration of DA from the
compound patch system could be maintained within the
therapeutic range and the pharmacokinetic behavior was
similarwith the commercial patch system.The drug loading of
DA from the compound patch was less than the commercial
patch, but the relative bioavailability of DA was 126.03%,
which implied the compound patch was superior to the
commercial patch. The study showed that 20 mg of lefluno-
mide daily was more effective than 10 mg without compro-
mising tolerability [25]. However, themost of RA patients were
elderwhose liver and kidney functions began to decline, 10mg
was recommended to supply [25]. The absolute bioavailability
of TEF in the compound patchwas 42%approximately, and the
designed daily dosage was 15 mg, which could reach thera-
peutic drug levels. Therefore, the loading dose of TEF in the
optimal formulation was reasonable.
3.4. Pharmacodynamic study
3.4.1. Anti-inflammatory activity
The anti-inflammatory effect of self-made compound trans-
dermal patch was evaluated by continuously measuring the
change in paw volume of adjuvant arthritismodel rat after the
administration of patches. The results were shown in Fig. 7.
Compared with the blank control group, all other groups
showed significant swelling at 0.5 d after the injection of CFA
of challenging reached a stable volume at the 5th day after
injection. The difference in swelling degree between negative
group and blank control group remained statistically signifi-
cant after administration, which indicated thematrix of patch
alone had no effect for adjuvant arthritis. Starting from the
7th day, the bilateral paw swellings of TEF group, DA group
and DA/TEF group were all reduced significantly compared
with the control group, indicating that the all of three types of
patches could inhibit the paw swelling of adjuvant arthritis
rat. In addition, even though no significant difference was
found between TEF group and DA group, the compound DA/
TEF group exhibited significantly superiority over the TEF-
TEtA and DA-TEtA group (P < 0.05). The resultsdemonstrated both of single TEF and DA patch had anti-
inflammatory effect, but their combination had stronger
anti-inflammatory effect than these two single drug con-
tained patches. The DA/TEF group was even superior to the
positive group in the rate of inhibiting inflammatory. Espe-
cially at the 9th day, this difference appearedmore significant
(P < 0.05). DA was a non-selective cyclooxygenase-1/2 inhibi-
tor, which could reduce inflammation [26], and TEF, an iso-
xazole derivative and inhibitor of de nove pyrimidine
synthesis, has been shown to provide comparable suppres-
sion of joint inflammation [27]. In conclusion, the compound
Table 4 e The results of analgesic effect of TEF and DA
patch on the pain of mice induced by acetic acid (n ¼ 10).
Group Dose WRF PIR (%)
Control e 38.33 ± 17.95 e
Negative e 37.40 ± 21.15 2.43
Positive 10 mg 12.60 ± 11.84*** 67.13
TEF 1.5 mg 31.50 ± 12.58 17.81
DA 5 mg 16.10 ± 11.66*** 58
DA/TEF 1.5 mg/5 mg 10.00 ± 6.31*** 73.91
***P < 0.001 vs. Control.
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apy. On the other hand, there was no significant difference for
swelling between left hind paw and right hind paw in all
groups. From this perspective, we could infer that the trans-
dermal patch's therapeutic effect for RA was via circulatory
system [12].
3.4.2. Analgesic activity
Writhing test induced by the acetic acid was a highly sensitive
and useful test to evaluate the effect of the analgesic drug. As
showed in Table 4, the obvious analgesic effect of the positive
group and DA/TEF group was observed, and there was no
significant difference (P > 0.05) between them. It was sug-
gested that the compound patch had an outstanding analgesic
effect. TEF group had little analgesic effect compared with the
control group. This is mainly due to different action mecha-
nism of DA and TEF. NSAIDs were preferred over analgesics
for pain management [28], but DMARDs prevented the pro-
gression of joint destruction and reduced the rate of radio-
logically detected joint damage and reversed disability [27].4. Conclusion
The results of this paper showed that DA-TEtA, the organic
salt of DA confirmed by DSC and FTIR can significantly in-
crease the percutaneous permeability of DA. DA-TEtA and
TEF-TEtA contained patch was prepared and the formulation
was optimized. The optimal foumulation is 2% of TEF-TEtA,
6% of DA-TEtA and 10% of AZ. The optimal compound patch
presented better anti-inflammatory and analgesic effects in
the study of adjuvant arthritis in rats and acetic acid-induced
writhing syndrome in mice, respectively. In conclusion, the
combined administration of DA-TEtA and TEF-TEtA for RA
treatment is feasible and promising.r e f e r e n c e s
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